Lurker Nancy
Insider CIK 1450485 · PDII CEO, Director · AUXL Director · COLL Director · PSDV President and CEO, Director · AQST Director · ALKS Director · MNK Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ALKS Alkermes plc. | M Exercise deriv | 2026-05-21 | 2026-05-22 | 6,142 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2026-05-21 | 2026-05-22 | 6,142 | — | $0 | 19,697 | SEC↗ |
| ALKS Alkermes plc. | F Tax w/h | 2026-05-21 | 2026-05-22 | 1,475 | $36.95 | $54.5K | 18,222 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2026-05-20 | 2026-05-22 | 5,409 | — | $0 | 5,409 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2026-05-20 | 2026-05-22 | 11,538 | — | $0 | 11,538 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2026-05-14 | 2026-05-18 | 8,741 | — | $0 | 26,758 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2026-05-13 | 2026-05-15 | 4,500 | $35.97 | $161.9K | 18,017 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2026-04-11 | 2026-04-13 | 3,751 | — | $0 | 3,752 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2026-04-11 | 2026-04-13 | 3,751 | — | $0 | 14,456 | SEC↗ |
| ALKS Alkermes plc. | F Tax w/h | 2026-04-11 | 2026-04-13 | 901 | $33.36 | $30.1K | 13,555 | SEC↗ |
| EYPT EyePoint, Inc. | M Exercise deriv | 2026-01-06 | 2026-01-07 | 75,133 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint, Inc. | M Exercise | 2026-01-06 | 2026-01-07 | 75,133 | — | $0 | 294,346 | SEC↗ |
| EYPT EyePoint, Inc. | M Exercise deriv | 2026-01-05 | 2026-01-06 | 12,666 | — | $0 | 12,667 | SEC↗ |
| EYPT EyePoint, Inc. | M Exercise | 2026-01-05 | 2026-01-06 | 12,666 | — | $0 | 219,213 | SEC↗ |
| EYPT EyePoint, Inc. | A Award deriv | 2026-01-02 | 2026-01-06 | 40,000 | — | $0 | 40,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2025-12-04 | 2025-12-05 | 9,300 | $15.11 | $140.5K | 206,547 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2025-11-28 | 2025-12-01 | 500 | $14.95 | $7.5K | 215,847 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2025-11-26 | 2025-12-01 | 200 | $14.95 | $3.0K | 216,347 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2025-07-10 | 2025-07-11 | 11,111 | — | $0 | 11,112 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2025-07-10 | 2025-07-11 | 11,111 | — | $0 | 216,547 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2025-07-02 | 2025-07-02 | 103,308 | — | $0 | 272,358 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2025-07-02 | 2025-07-02 | 103,308 | — | $0 | 178,442 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2025-07-02 | 2025-07-02 | 55,000 | — | $0 | 200,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2025-07-02 | 2025-07-02 | 31,165 | — | $0 | 213,700 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2025-07-02 | 2025-07-02 | 31,165 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2025-07-02 | 2025-07-02 | 15,278 | — | $0 | 34,722 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2025-07-02 | 2025-07-02 | 15,278 | — | $0 | 31,944 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2025-07-02 | 2025-07-02 | 27,270 | — | $0 | 49,730 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2025-07-02 | 2025-07-02 | 27,270 | — | $0 | 27,270 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2025-07-02 | 2025-07-02 | 55,000 | — | $0 | 40,000 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2025-05-31 | 2025-06-02 | 8,013 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | F Tax w/h | 2025-05-31 | 2025-06-02 | 1,924 | $30.61 | $58.9K | 10,705 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2025-05-31 | 2025-06-02 | 8,013 | — | $0 | 12,629 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2025-05-21 | 2025-05-23 | 6,142 | — | $0 | 6,142 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2025-05-21 | 2025-05-23 | 13,474 | — | $0 | 13,474 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2025-05-15 | 2025-05-19 | 9,791 | — | $0 | 22,517 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2025-04-11 | 2025-04-14 | 3,752 | — | $0 | 7,503 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2025-04-11 | 2025-04-14 | 2,323 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | F Tax w/h | 2025-04-11 | 2025-04-14 | 558 | $27.00 | $15.1K | 1,765 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2025-04-11 | 2025-04-14 | 3,752 | — | $0 | 5,517 | SEC↗ |
| ALKS Alkermes plc. | F Tax w/h | 2025-04-11 | 2025-04-14 | 901 | $27.00 | $24.3K | 4,616 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2025-04-11 | 2025-04-14 | 2,323 | — | $0 | 2,323 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2025-02-09 | 2025-02-11 | 20,000 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2025-02-09 | 2025-02-11 | 20,000 | — | $0 | 205,436 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2025-02-04 | 2025-02-05 | 12,726 | — | $0 | 12,726 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2025-01-06 | 2025-01-07 | 75,134 | — | $0 | 75,133 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2025-01-06 | 2025-01-07 | 75,134 | — | $0 | 185,436 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2025-01-05 | 2025-01-07 | 12,667 | — | $0 | 25,333 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2025-01-05 | 2025-01-07 | 12,667 | — | $0 | 110,302 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2025-01-03 | 2025-01-07 | 40,000 | — | $0 | 40,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2024-08-16 | 2024-08-20 | 3,173 | $7.88 | $25.0K | 97,635 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-07-26 | 2024-07-26 | 30,000 | — | $0 | 95,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-07-26 | 2024-07-26 | 1,558 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-07-26 | 2024-07-26 | 1,558 | — | $0 | 74,800 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-07-26 | 2024-07-26 | 26,713 | — | $0 | 31,165 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-07-26 | 2024-07-26 | 26,713 | — | $0 | 182,535 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-07-26 | 2024-07-26 | 16,666 | — | $0 | 50,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-07-26 | 2024-07-26 | 30,000 | — | $0 | 145,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-07-26 | 2024-07-26 | 56,350 | — | $0 | 281,750 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-07-26 | 2024-07-26 | 56,350 | — | $0 | 169,050 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-07-26 | 2024-07-26 | 16,666 | — | $0 | 16,666 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-07-10 | 2024-07-12 | 11,111 | — | $0 | 22,223 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-07-10 | 2024-07-12 | 11,111 | — | $0 | 94,462 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2024-05-31 | 2024-06-04 | 17,492 | — | $0 | 17,492 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2024-05-31 | 2024-06-04 | 8,013 | — | $0 | 8,013 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2024-04-11 | 2024-04-12 | 2,323 | — | $0 | 2,323 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2024-04-11 | 2024-04-12 | 11,255 | — | $0 | 11,255 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2024-04-11 | 2024-04-12 | 22,103 | — | $0 | 22,103 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2024-04-11 | 2024-04-12 | 4,833 | — | $0 | 4,833 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-02-13 | 2024-02-13 | 4,452 | — | $0 | 155,822 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-02-13 | 2024-02-13 | 4,452 | — | $0 | 57,878 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-02-13 | 2024-02-13 | 3,116 | — | $0 | 73,242 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-02-13 | 2024-02-13 | 5,000 | — | $0 | 115,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-02-13 | 2024-02-13 | 5,000 | — | $0 | 125,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-02-13 | 2024-02-13 | 3,116 | — | $0 | 1,558 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift | 2024-02-13 | 2024-02-13 | 74,681 | — | $0 | 126,889 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift | 2024-02-13 | 2024-02-13 | 74,681 | — | $0 | 83,351 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-02-09 | 2024-02-13 | 20,000 | — | $0 | 20,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-02-09 | 2024-02-13 | 17,534 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-02-09 | 2024-02-13 | 6,981 | $28.80 | $201.1K | 158,032 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-02-09 | 2024-02-13 | 7,962 | $28.80 | $229.3K | 165,013 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-02-09 | 2024-02-13 | 17,534 | — | $0 | 172,975 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-02-09 | 2024-02-13 | 20,000 | — | $0 | 155,441 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-01-24 | 2024-01-25 | 112,700 | — | $0 | 338,100 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2024-01-24 | 2024-01-25 | 112,700 | — | $0 | 112,700 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-24 | 2024-01-25 | 29,956 | $24.98 | $748.3K | 135,441 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-23 | 2024-01-25 | 5,044 | $24.97 | $125.9K | 165,397 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-06 | 2024-01-09 | 75,133 | — | $0 | 150,267 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-06 | 2024-01-09 | 75,133 | — | $0 | 193,484 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-01-06 | 2024-01-09 | 23,043 | $20.40 | $470.1K | 170,441 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2024-01-05 | 2024-01-09 | 38,000 | — | $0 | 38,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2024-01-05 | 2024-01-09 | 77,000 | — | $0 | 77,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-02 | 35,000 | — | $0 | 110,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-02 | 31,164 | — | $0 | 62,330 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-02 | 31,164 | — | $0 | 151,370 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-02 | 35,000 | — | $0 | 130,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-02 | 10,906 | — | $0 | 70,126 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-02 | 10,906 | — | $0 | 4,674 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-03 | 35,000 | — | $0 | 110,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-03 | 35,000 | — | $0 | 130,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-03 | 10,906 | — | $0 | 70,126 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-03 | 10,906 | — | $0 | 4,674 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-03 | 31,164 | — | $0 | 151,370 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-12-28 | 2024-01-03 | 31,164 | — | $0 | 62,330 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift | 2023-12-28 | 2024-01-03 | 52,208 | — | $0 | 118,351 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift | 2023-12-28 | 2024-01-03 | 52,208 | — | $0 | 52,208 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2023-12-04 | 2023-12-06 | 20,000 | $20.76 | $415.2K | 170,559 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2023-07-10 | 2023-07-12 | 33,334 | — | $0 | 33,334 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2023-07-10 | 2023-07-12 | 66,666 | — | $0 | 66,666 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2023-06-20 | 2023-06-22 | 225,400 | — | $0 | 225,400 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 21,250 | — | $0 | 85,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 21,250 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 65,868 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 65,868 | — | $0 | 93,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 75,000 | — | $0 | 75,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 75,000 | — | $0 | 165,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 59,220 | — | $0 | 59,220 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 59,220 | — | $0 | 15,580 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 120,206 | — | $0 | 120,206 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 120,206 | — | $0 | 93,494 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 8,000 | — | $0 | 24,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 8,000 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 36,000 | — | $0 | 54,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | G Gift deriv | 2023-05-11 | 2023-05-15 | 36,000 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2023-02-09 | 2023-02-13 | 17,533 | — | $0 | 17,534 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2023-02-09 | 2023-02-13 | 20,000 | — | $0 | 40,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2023-02-09 | 2023-02-13 | 17,533 | — | $0 | 170,559 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2023-02-09 | 2023-02-13 | 20,000 | — | $0 | 190,559 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2023-01-06 | 2023-01-10 | 450,800 | — | $0 | 450,800 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2022-02-28 | 2022-03-02 | 12,466 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2022-02-28 | 2022-03-02 | 12,466 | — | $0 | 150,281 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2022-02-21 | 2022-02-23 | 13,717 | — | $0 | 13,718 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2022-02-21 | 2022-02-23 | 13,717 | — | $0 | 137,815 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2022-02-09 | 2022-02-11 | 240,000 | — | $0 | 240,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2022-02-09 | 2022-02-11 | 60,000 | — | $0 | 60,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2022-02-09 | 2022-02-11 | 17,533 | — | $0 | 35,067 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2022-02-09 | 2022-02-11 | 17,533 | — | $0 | 124,098 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2021-11-15 | 2021-11-17 | 10,000 | $20.15 | $201.5K | 103,546 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2021-06-22 | 2021-06-23 | 52,600 | — | $0 | 52,600 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2021-06-22 | 2021-06-23 | 213,700 | — | $0 | 213,700 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award deriv | 2021-06-15 | 2021-06-17 | 20,000 | — | $0 | 20,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2021-06-14 | 2021-06-15 | 4,500 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2021-06-14 | 2021-06-15 | 4,500 | — | $0 | 113,546 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2021-02-28 | 2021-03-02 | 12,467 | — | $0 | 12,466 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2021-02-28 | 2021-03-02 | 12,467 | — | $0 | 109,046 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2021-02-21 | 2021-02-23 | 13,717 | — | $0 | 13,718 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2021-02-21 | 2021-02-23 | 13,717 | — | $0 | 96,579 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2020-06-30 | 2020-07-02 | 124,667 | — | $0 | 249,333 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2020-06-30 | 2020-07-02 | 124,667 | — | $0 | 784,467 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2020-06-27 | 2020-06-30 | 40,000 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2020-06-27 | 2020-06-30 | 40,000 | — | $0 | 659,800 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award deriv | 2020-06-16 | 2020-06-18 | 14,000 | — | $0 | 14,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2020-06-14 | 2020-06-16 | 45,000 | — | $0 | 45,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2020-06-14 | 2020-06-16 | 45,000 | — | $0 | 619,800 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2020-03-10 | 2020-03-11 | 98,000 | $1.06 | $103.9K | 574,800 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2020-02-28 | 2020-03-03 | 748,000 | — | $0 | 748,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2020-02-28 | 2020-03-03 | 374,000 | — | $0 | 374,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2020-02-21 | 2020-02-25 | 137,174 | — | $0 | 274,349 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2020-02-21 | 2020-02-25 | 137,174 | — | $0 | 476,800 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2019-10-12 | 2019-10-15 | 10,745 | $2.11 | $22.7K | 314,455 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2019-06-27 | 2019-06-28 | 40,000 | — | $0 | 40,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2019-06-27 | 2019-06-28 | 40,000 | — | $0 | 325,200 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2019-06-25 | 2019-06-27 | 930,000 | — | $0 | 930,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2019-06-25 | 2019-06-27 | 411,523 | — | $0 | 411,523 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2019-06-14 | 2019-06-17 | 45,000 | — | $0 | 90,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2019-06-14 | 2019-06-17 | 45,000 | — | $0 | 285,200 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award deriv | 2019-06-13 | 2019-06-17 | 13,350 | — | $0 | 13,350 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2019-03-29 | 2019-04-01 | 28,500 | $1.76 | $50.2K | 240,200 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award | 2018-10-12 | 2018-10-16 | 76,667 | — | $0 | 211,700 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award deriv | 2018-07-24 | 2018-07-26 | 26,700 | — | $0 | 26,700 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2018-06-27 | 2018-06-29 | 40,000 | — | $0 | 80,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2018-06-27 | 2018-06-29 | 40,000 | — | $0 | 135,033 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2018-06-14 | 2018-06-18 | 135,000 | — | $0 | 135,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2018-06-14 | 2018-06-18 | 540,000 | — | $0 | 540,000 | SEC↗ |
| PSDV pSivida Corp. | A Award | 2018-03-19 | 2018-03-21 | 38,333 | — | $0 | 95,033 | SEC↗ |
| PSDV pSivida Corp. | A Award deriv | 2017-12-15 | 2017-12-19 | 240,000 | — | $0 | 240,000 | SEC↗ |
| PSDV pSivida Corp. | A Award deriv | 2017-12-15 | 2017-12-19 | 120,000 | — | $0 | 120,000 | SEC↗ |
| PSDV pSivida Corp. | P Buy | 2017-06-14 | 2017-06-14 | 56,700 | $1.76 | $99.8K | 56,700 | SEC↗ |
| PSDV pSivida Corp. | A Award deriv | 2016-12-12 | 2016-12-14 | 850,000 | — | $0 | 850,000 | SEC↗ |
| MNK Mallinckrodt plc | A Award | 2016-03-16 | 2016-03-18 | 4,041 | — | $0 | 10,965 | SEC↗ |
| MNK Mallinckrodt plc | F Tax w/h | 2016-03-16 | 2016-03-18 | 458 | $55.69 | $25.5K | 10,507 | SEC↗ |
| MNK Mallinckrodt plc | A Award | 2015-03-19 | 2015-03-23 | 1,715 | — | $0 | 6,924 | SEC↗ |
| PDII PDI INC | A Award | 2015-03-05 | 2015-03-09 | 444,364 | $1.73 | $768.7K | 871,681 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | J Other deriv | 2015-01-29 | 2015-01-30 | 5,000 | $36.53 | $182.7K | 0 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | J Other | 2015-01-29 | 2015-01-30 | 10,000 | $36.53 | $365.3K | 0 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | M Exercise deriv | 2014-12-05 | 2014-12-08 | 15,000 | — | $0 | 0 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | M Exercise deriv | 2014-12-05 | 2014-12-08 | 5,000 | — | $0 | 0 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | M Exercise deriv | 2014-12-05 | 2014-12-08 | 5,000 | — | $0 | 0 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | S Sale | 2014-12-05 | 2014-12-08 | 7,430 | $34.00 | $252.6K | 10,000 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | M Exercise | 2014-12-05 | 2014-12-08 | 15,000 | $19.78 | $296.7K | 32,430 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | M Exercise | 2014-12-05 | 2014-12-08 | 5,000 | $24.62 | $123.1K | 37,430 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | M Exercise | 2014-12-05 | 2014-12-08 | 5,000 | $14.37 | $71.8K | 42,430 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | S Sale | 2014-12-05 | 2014-12-08 | 25,000 | $34.00 | $850.0K | 17,430 | SEC↗ |
| PDII PDI INC | P Buy | 2014-11-10 | 2014-11-12 | 16,000 | $1.69 | $27.0K | 533,317 | SEC↗ |
| PDII PDI INC | P Buy | 2014-11-07 | 2014-11-12 | 33,000 | $1.77 | $58.4K | 517,317 | SEC↗ |
| PDII PDI INC | P Buy | 2014-11-06 | 2014-11-07 | 1,000 | $1.60 | $1.6K | 490,403 | SEC↗ |
| PDII PDI INC | P Buy | 2014-11-05 | 2014-11-07 | 500 | $1.72 | $860 | 489,403 | SEC↗ |
| PDII PDI INC | P Buy | 2014-11-05 | 2014-11-07 | 27,500 | $1.74 | $47.9K | 460,903 | SEC↗ |
| PDII PDI INC | P Buy | 2014-11-05 | 2014-11-07 | 27,500 | $1.75 | $48.1K | 488,403 | SEC↗ |
| PDII PDI INC | P Buy | 2014-11-05 | 2014-11-07 | 500 | $1.72 | $860 | 488,903 | SEC↗ |
| MNK Mallinckrodt plc | A Award | 2014-05-22 | 2014-05-27 | 572 | — | $0 | 5,209 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award deriv | 2014-05-21 | 2014-05-22 | 5,000 | — | $0 | 5,000 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award | 2014-05-21 | 2014-05-22 | 5,000 | — | $0 | 17,430 | SEC↗ |
| PDII PDI INC | F Tax w/h | 2014-03-25 | 2014-03-27 | 23,316 | $4.91 | $114.5K | 433,403 | SEC↗ |
| MNK Mallinckrodt plc | F Tax w/h | 2014-03-20 | 2014-03-24 | 971 | $69.95 | $67.9K | 4,637 | SEC↗ |
| MNK Mallinckrodt plc | A Award | 2014-03-20 | 2014-03-24 | 2,574 | — | $0 | 5,608 | SEC↗ |
| PDII PDI INC | A Award deriv | 2014-02-26 | 2014-02-28 | 188,165 | — | $0 | 678,116 | SEC↗ |
| PDII PDI INC | A Award deriv | 2014-02-26 | 2014-02-28 | 177,665 | — | $0 | 489,951 | SEC↗ |
| PDII PDI INC | A Award | 2014-02-26 | 2014-02-28 | 63,177 | $5.10 | $322.2K | 456,719 | SEC↗ |
| PDII PDI INC | A Award | 2014-02-26 | 2014-02-28 | 10,584 | $5.10 | $54.0K | 393,542 | SEC↗ |
| MNK Mallinckrodt plc | A Award | 2013-07-18 | 2013-07-22 | 3,034 | — | $0 | 3,034 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award deriv | 2013-05-01 | 2013-05-03 | 5,000 | — | $0 | 5,000 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award | 2013-05-01 | 2013-05-03 | 5,000 | — | $0 | 12,430 | SEC↗ |
| PDII PDI INC | A Award deriv | 2013-04-04 | 2013-04-08 | 141,700 | — | $0 | 592,286 | SEC↗ |
| PDII PDI INC | A Award | 2013-04-04 | 2013-04-08 | 51,320 | $5.44 | $279.2K | 382,958 | SEC↗ |
| PDII PDI INC | F Tax w/h | 2013-03-01 | 2013-03-05 | 16,279 | $7.43 | $121.0K | 331,638 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award | 2012-06-29 | 2012-07-03 | 417 | $26.89 | $11.2K | 7,430 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award deriv | 2012-06-21 | 2012-06-22 | 5,000 | — | $0 | 5,000 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award | 2012-06-21 | 2012-06-22 | 5,000 | — | $0 | 7,013 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award | 2012-03-30 | 2012-04-03 | 605 | $18.57 | $11.2K | 2,013 | SEC↗ |
| PDII PDI INC | A Award deriv | 2012-01-31 | 2012-02-01 | 111,684 | — | $0 | 450,586 | SEC↗ |
| PDII PDI INC | A Award | 2012-01-31 | 2012-02-01 | 50,702 | $6.41 | $325.0K | 347,917 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award | 2011-12-30 | 2012-01-04 | 563 | $19.93 | $11.2K | 1,408 | SEC↗ |